Vimarsana
Biggest News Aggregation in the World

Capital Transactions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Capital Transactions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Capital Transactions Today - Breaking & Trending Today

Assam's vision for sustainable growth - Vimarsana News

Assam's vision for sustainable growth

The Assam Budget for 2024–25 outlines key priorities aimed at fostering self-reliance in the state.

Jones Lang LaSalle Incorporated : Joint venture equity arranged for a multi-use industrial portfolio in New Jersey and Pennsylvania -October 26, 2023 at 04:41 pm EDT - Vimarsana News

Jones Lang LaSalle Incorporated : Joint venture equity arranged for a multi-use industrial portfolio in New Jersey and Pennsylvania -October 26, 2023 at 04:41 pm EDT

MORRISTOWN, N.J., Oct. 26, 2023 - JLL Capital Markets announced today that it arranged joint venture equity on behalf of Denholtz Properties for the recap of a portfolio of 16 light-industrial...

Petrobras : PETRÓLEO BRASILEIRO S.A. – PETROBRAS - Form 6-K - Vimarsana News

Petrobras : PETRÓLEO BRASILEIRO S.A. – PETROBRAS - Form 6-K

Third parties Expected credit losses - Related parties ... | May 12, 2023

Denholtz acquires 359K-square-foot Georgia industrial portfolio - Vimarsana News

Denholtz acquires 359K-square-foot Georgia industrial portfolio

Denholtz Properties acquired Coleman Portfolio: a fully leased, three-building, 358,884-square-foot industrial portfolio located in Savannah.

Source: njbiz.com
Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update - Vimarsana News

Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update

01.09.2022 - - On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic IV - Focused entry into US market with Maxigesic IV for non-opioid pain treatment; continuing ...